Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 37 min ago
Peer-reviewedCC BY 4.0ACS Omega

Use of Tamoxifen Derivatives in Combination with Colistin against Colistin-Resistant Acinetobacter baumannii

  • Irene Molina Panadero1
  • Angela Rey Hidalgo1
  • Isabella Rimoldi2
  • Giorgio Facchetti2
  • Michael S. Christodoulou3
  • Younes Smani1,4
4 affiliations
  1. 1Universidad Pablo de Olavide/Consejo Superior de Investigaciones Científicas/Junta de Andalucía , , ,
  2. 2Università degli Studi di Milano , , Via Golgi 19 , ,
  3. 3University of Milan , , Via Celoria 2 , ,
  4. 4Universidad Pablo de Olavide , , ,
Read full textPDFDOICite

Abstract

Drug repurposing has led to the identification of tamoxifen, a well-known chemotherapy drug, as a compound with relevant antibacterial properties. In this field, the development of new tamoxifen derivatives with antimicrobial activity, particularly against colistin-resistant Acinetobacter baumannii, represents an important area of research. We evaluated the MICs of 22 and 3 tamoxifen derivatives against wild-type and colistin-resistant A. baumannii strains, respectively, using microdilution assays, either as monotherapy or in combination with colistin. While all derivatives showed MIC values above 64 mg/L when tested as monotherapy, combining derivatives 1, 14, and 18 with colistin reduced tamoxifen derivatives’ MICs to 0.125–2 mg/L for the reference strain ATCC 17978 and to 0.5–1 mg/L for the colistin-resistant Ab22 strain. Growth assays showed that these derivatives delayed Ab22 proliferation during the first 4 h. Moreover, these derivatives increased membrane permeabilization without altering the expression of the outer membrane proteins (OMPs). These findings suggest that tamoxifen derivatives in combination with colistin exhibit antibacterial activity against a colistin-resistant A. baumannii, potentially broadening the spectrum of available drug treatments for combating MDR A. baumannii.

Related

  1. Outbreak of carbapenem-resistant Acinetobacter baumannii in post–haematopoietic stem cell transplantation patients potentially caused by drinking water contamination
    Xiaoyu Luo, Yinghua Zhang, Shihui Guo +6
    Infection prevention in practicePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Carbapenem-Resistant Acinetobacter baumannii Isolation and In-Hospital Mortality in Adults Hospitalized with COVID-19 in Romania: A Retrospective Single-Center Cohort Study
    Cristiana Georgeta Bujor, Marilena Dinuti, Felicia Sfrijan
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  3. Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review
    Luca Pipitò, Eleonora Bono, Chiara Vincenza Mazzola +1
    InfectionPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  4. Molecular evidence of a dominant multidrug resistant Acinetobacter baumannii lineage in a tertiary hospital in northern Peru.
    Kevin G Quispe Choque, Nataly Ruiz Quiñones, Milena Binatti Ferreira +5
    New microbes and new infectionsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Cost-Effectiveness of Sulbactam-durlobactam Compared with Colistin for Treating Carbapenem-Resistant Acinetobacter baumannii Infections in Critical Care Settings in the United States
    A. Ologunowa, A. Caffrey, S. Cohen +1
    medRxivPreprintCC BYFull textInfectious diseasemedRxiv

Cite

BibTeXRIS
BibTeX
@article{panadero2026tamoxifen,
  title = {{Use of Tamoxifen Derivatives in Combination with Colistin against Colistin-Resistant Acinetobacter baumannii}},
  author = {Irene Molina Panadero and Angela Rey Hidalgo and Isabella Rimoldi and Giorgio Facchetti and Michael S. Christodoulou and Younes Smani},
  journal = {ACS Omega},
  year = {2026},
  month = oct,
  doi = {10.1021/acsomega.6c05050},
  url = {https://pubs.acs.org/acsodf/article/11/41/62936/5446583/Use-of-Tamoxifen-Derivatives-in-Combination-with},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Use of Tamoxifen Derivatives in Combination with Colistin against Colistin-Resistant Acinetobacter baumannii
AU  - Irene Molina Panadero
AU  - Angela Rey Hidalgo
AU  - Isabella Rimoldi
AU  - Giorgio Facchetti
AU  - Michael S. Christodoulou
AU  - Younes Smani
PY  - 2026
DA  - 2026/10/07
JO  - ACS Omega
DO  - 10.1021/acsomega.6c05050
UR  - https://pubs.acs.org/acsodf/article/11/41/62936/5446583/Use-of-Tamoxifen-Derivatives-in-Combination-with
AB  - Drug repurposing has led to the identification of tamoxifen, a well-known chemotherapy drug, as a compound with relevant antibacterial properties. In this field, the development of new tamoxifen derivatives with antimicrobial activity, particularly against colistin-resistant Acinetobacter baumannii, represents an important area of research. We evaluated the MICs of 22 and 3 tamoxifen derivatives against wild-type and colistin-resistant A. baumannii strains, respectively, using microdilution assays, either as monotherapy or in combination with colistin. While all derivatives showed MIC values above 64 mg/L when tested as monotherapy, combining derivatives 1, 14, and 18 with colistin reduced tamoxifen derivatives’ MICs to 0.125–2 mg/L for the reference strain ATCC 17978 and to 0.5–1 mg/L for the colistin-resistant Ab22 strain. Growth assays showed that these derivatives delayed Ab22 proliferation during the first 4 h. Moreover, these derivatives increased membrane permeabilization without altering the expression of the outer membrane proteins (OMPs). These findings suggest that tamoxifen derivatives in combination with colistin exhibit antibacterial activity against a colistin-resistant A. baumannii, potentially broadening the spectrum of available drug treatments for combating MDR A. baumannii.
SN  - 2470-1343
ER  -